An asymptomatic male patient with definite LQTS with a normal ECG and QTc who was flagged by the AI. Photo Credit: J. Martijn Bos and Michael Ackerman. A new artificial intelligence (AI) solution ...

HeartBeam, Inc. (BEAT) (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that the U.S. Food and Drug ...

HeartBeam has received FDA clearance for its synthesized 12-lead ECG software, making it the first cable-free device of its kind for at-home arrhythmia assessment. The clearance followed a successful ...

The company notes the synthesized output is not intended to replace a standard 12-lead ECG. HeartBeam also plans to advance development of an on-demand 12-lead ECG extended wear monitor and build ...

Telemed Solutions, a cardiac device company, announced today the release of its initial product, the TM-12. The TM-12 is a PC-based wireless 12-Lead EKG system. It embeds a Bluetooth radio into an ECG ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, ...

Clearance for First-Ever Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment Pivotal Milestone Unlocks ...

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through advanced cardiac insights ...